State-of-the-art and recent advances in quantification for therapeutic follow-up in oncology using PET

18F-fluoro-2-deoxyglucose (18F-FDG) positron emission tomography (PET) is an important tool in oncology. Its use has greatly progressed from initial diagnosis to staging and patient monitoring. The information derived from 18F-FDG-PET allowed the development of a wide range of PET quantitative analy...

Full description

Bibliographic Details
Main Authors: Thomas eCarlier, Clément eBailly
Format: Article
Language:English
Published: Frontiers Media S.A. 2015-03-01
Series:Frontiers in Medicine
Subjects:
PET
Online Access:http://journal.frontiersin.org/Journal/10.3389/fmed.2015.00018/full
id doaj-2fa5e5a58c254220b22ac4c810078213
record_format Article
spelling doaj-2fa5e5a58c254220b22ac4c8100782132020-11-24T23:25:29ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2015-03-01210.3389/fmed.2015.00018126051State-of-the-art and recent advances in quantification for therapeutic follow-up in oncology using PETThomas eCarlier0Clément eBailly1University hospital of NantesUniversity hospital of Nantes18F-fluoro-2-deoxyglucose (18F-FDG) positron emission tomography (PET) is an important tool in oncology. Its use has greatly progressed from initial diagnosis to staging and patient monitoring. The information derived from 18F-FDG-PET allowed the development of a wide range of PET quantitative analysis techniques ranging from simple semi-quantitative methods like the standardised uptake value (SUV) to high order metrics that require a segmentation step and additional image processing. In this review, these methods are discussed, focusing particularly on the available methodologies that can be used in clinical trials as well as their current applications in international consensus for PET interpretation in lymphoma and solid tumors.http://journal.frontiersin.org/Journal/10.3389/fmed.2015.00018/fullNuclear MedicinePETfollow-uponcologyquantification
collection DOAJ
language English
format Article
sources DOAJ
author Thomas eCarlier
Clément eBailly
spellingShingle Thomas eCarlier
Clément eBailly
State-of-the-art and recent advances in quantification for therapeutic follow-up in oncology using PET
Frontiers in Medicine
Nuclear Medicine
PET
follow-up
oncology
quantification
author_facet Thomas eCarlier
Clément eBailly
author_sort Thomas eCarlier
title State-of-the-art and recent advances in quantification for therapeutic follow-up in oncology using PET
title_short State-of-the-art and recent advances in quantification for therapeutic follow-up in oncology using PET
title_full State-of-the-art and recent advances in quantification for therapeutic follow-up in oncology using PET
title_fullStr State-of-the-art and recent advances in quantification for therapeutic follow-up in oncology using PET
title_full_unstemmed State-of-the-art and recent advances in quantification for therapeutic follow-up in oncology using PET
title_sort state-of-the-art and recent advances in quantification for therapeutic follow-up in oncology using pet
publisher Frontiers Media S.A.
series Frontiers in Medicine
issn 2296-858X
publishDate 2015-03-01
description 18F-fluoro-2-deoxyglucose (18F-FDG) positron emission tomography (PET) is an important tool in oncology. Its use has greatly progressed from initial diagnosis to staging and patient monitoring. The information derived from 18F-FDG-PET allowed the development of a wide range of PET quantitative analysis techniques ranging from simple semi-quantitative methods like the standardised uptake value (SUV) to high order metrics that require a segmentation step and additional image processing. In this review, these methods are discussed, focusing particularly on the available methodologies that can be used in clinical trials as well as their current applications in international consensus for PET interpretation in lymphoma and solid tumors.
topic Nuclear Medicine
PET
follow-up
oncology
quantification
url http://journal.frontiersin.org/Journal/10.3389/fmed.2015.00018/full
work_keys_str_mv AT thomasecarlier stateoftheartandrecentadvancesinquantificationfortherapeuticfollowupinoncologyusingpet
AT clementebailly stateoftheartandrecentadvancesinquantificationfortherapeuticfollowupinoncologyusingpet
_version_ 1725557234829623296